The MARGOT trial (NCT04425018) is currently evaluating the role of personalized treatment of stage II-III HER2+ BC in patients with the FF or FV CD16A genotype with paclitaxel plus margetuximab and pertuzumab vs paclitaxel plus trastuzumab and pertuzumab (22). Here, ERBB2 is linked to breast cancer.